| INTRODUC TI ON
Opioid analgesics are important for the management of moderateto-severe chronic pain. The prevalence of long-term opioid use in the United States is estimated to be 40-46 people per 1000 individuals. 1 However, the clinical benefit of opioid analgesics is compromised by their side effects, which include nausea, bowel dysfunction including opioid-induced constipation (OIC), and central nervous system events such as confusion, headache, and hallucination. [2] [3] [4] [5] OIC is one of the most common and debilitating side effects of opioids and is characterized by a reduction in bowel movement frequency, development or worsening of straining while passing stool, sense of incomplete bowel evacuation, and hard-stool formation after initiation of opioid therapy. [6] [7] [8] [9] [10] Opioid analgesics act via the μ-, δ-, and κ-opioid receptors distributed widely in the central and peripheral nervous system. Although the role of δ-and κ-opioid receptors in causing gastrointestinal adverse events is less clear, μ-opioid receptors are expressed throughout the gastrointestinal tract and, upon opioid binding, decrease neural activity in the enteric nervous system. This impairs motility and transit throughout the gastrointestinal tract, reduces the secretion of gut fluid, and increases fluid absorption, resulting in OIC. 8 Laxatives, often used as first-line treatment for OIC, are associated with limited efficacy and do not address the underlying mechanism of OIC. 2, 7 Peripherally acting μ-opioid receptor antagonists (PAMORAs) aim to reverse OIC by blocking opioid actions at peripheral μ-opioid receptors in the gastrointestinal tract without adversely affecting analgesia. 8 Currently, three PAMORAs are approved for OIC: naldemedine, 11 naloxegol (oral), 12, 13 and methylnaltrexone (oral or subcutaneous). 14 Another PAMORA, alvimopan, is approved for postoperative ileus following partial or small bowel resection with primary anastomosis. 15 Naldemedine (S-297995) is a PAMORA indicated for the treatment of OIC, as a once-daily oral drug, in adult patients with chronic noncancer pain in the United States and in patients with chronic noncancer pain and cancer in Japan. Naldemedine is an amide derivative of the opioid receptor antagonist naltrexone, but with structural modifications that limit its ability to cross the blood-brain barrier (BBB). In fact, naldemedine showed high oral bioavailability but poor distribution throughout the CNS in pharmacokinetics studies in rats, (the bioavailability and the brain-to-plasma concentration ratio of naldemedine at a dose of 1 mg kg −1 were 29% and 0.03, respectively). 16 The aims of the studies presented here were to determine the binding affinities and functional activities of naldemedine, to understand the pharmacologic effects of naldemedine in vitro and in vivo in animal models of OIC, and to determine the differences in the doses of naldemedine for treating OIC without impacting nociception or inducing morphine withdrawal.
| In vitro studies on specific binding affinities of naldemedine to opioid receptors and functional activities of naldemedine
The in vitro binding affinities and functional activities of naldemedine for recombinant human μ-, δ-, and κ-opioid receptors were determined and compared with that of the reference compound, methylnaltrexone, as previously described, 17 with some modifications.
Binding assays were used to determine the concentration of test substances that inhibited 50% of specific binding (IC 50 ), and the inhibition constant (K i ) value for each sample was calculated using the following equation: by naldemedine was less (<30%) than basal GTPγS binding levels.
In the functional antagonist assay, the K b value for the cellular assay was calculated as: K b = IC 50 /{(agonist/EC 50 ) + 1}; where IC 50 = the concentration of the antagonist producing 50% inhibition in the presence of agonist, and EC 50 = the concentration that produces half the maximal effect of the agonist.
| In vitro study of naldemedine specificity: enzyme inhibition and radioligand receptor binding assays
Naldemedine binding at a single concentration of 10 μmol L −1 was measured against receptors, channels, and transporters, and in functional enzyme assays, by Sekisui Medical Co., Ltd. (Tokyo, Japan).
Radioligand binding and enzyme inhibition studies were conducted using cell lines (recombinant or endogenous target expression), animal tissue, or purified enzymes.
| In vivo and ex vivo experiments: animals and procedures
All studies were conducted at Shionogi & Co., Ltd., except for the study involving the oxycodone-induced small intestinal transit model, which was conducted at the Shiga Laboratory of Nissei Bilis
Co., Ltd. (Osaka, Japan). The studies were conducted in accordance with standards of the Institutional Animal Care and Use Committee,
Institutional Animal Ethics Committee, and Shionogi's Institutional
Animal Care and Use Committee.
All Crlj: WI (Wistar) and Crl: CD (Sprague-Dawley) male rats were obtained from Charles River Laboratories Japan, Inc (Kanagawa, Japan). Jcl: Wistar rats were supplied by CLEA Japan, Inc (Tokyo, Japan). Hartley guinea pigs were obtained from Japan SLC, Inc (Shizuoka, Japan). All animals were maintained on 12-hour light/dark cycles and had free access to food and water. Rats were fasted for at least 20 hours for the small transit study and castor oil model, or 15-24 hours for the antinociceptive model to render the stomach, small intestine, and colon empty prior to the experiments, but received tap water ad libitum. On each experimental day, naldemedine (oral) and opioids were administered at a volume of 2 mL kg −1 at the doses and routes described below.
| Small intestinal transit
The antagonistic effect of naldemedine on constipation caused by morphine-or oxycodone-induced inhibition of small intestinal transit was determined and compared with methylnaltrexone, as previously described, 17 with some modifications. Briefly, 6-week-old Crlj:
WI male rats were allocated into groups (10-12 per group) based on body weight and administered naldemedine 0.001-10 mg kg were also calculated.
| Large intestinal transit
The antagonistic effect of naldemedine on the velocity inhibition of the propulsion constipation caused by morphine was determined as described previously 18, 19 with some modifications. Briefly, the large intestine was isolated from the guinea pig and placed in ice-cold Krebs solution until use. Five centimeters of distal colon was isolated and pinned on either end in the organ bath of the Gastrointestinal Motility
Monitoring system (GIMM; Catamount Research and Development;
St. Albans, VT, USA), and continuously perfused with 37°C warmed oxygenated Krebs solution at 10 mL min −1 as detailed previously. 18, 19 After >25 minutes of incubation, propulsion of a fecal pellet inserted from the oral end of the colon toward the anal end was monitored by a GIMM digital video camera. The velocity of the propulsion was measured on a 2-cm section of the colon using GIMM software. To measure the effect of naldemedine on the basal rate of propulsion, 
| Castor oil-induced diarrhea model
The antagonistic effect of naldemedine in a castor oil-induced diarrhea model was determined and compared with methylnaltrexone, as previously described 20 with some modifications. Briefly, 6-weekold Crl: CD male rats were allocated into nine groups (11 per group) based on body weight. Naldemedine (0.003-1 mg kg −1 ) or vehicle was administered, followed by 2 mL of castor oil intragastrically 45 minutes later, and subcutaneous morphine 1 mg kg −1 or saline 15 minutes thereafter.
Evaluations were conducted 60 minutes after morphine or saline administration. Each rat was individually transferred to a transparent observation cage with the floor covered with filter paper to absorb moisture. Castor oil-induced diarrhea was evaluated using a validated 3-point scale 21 for scoring symptoms: 0 = no diarrhea, 1 = mild diarrhea with loose bowel movements, and 2 = intense liquefied diarrhea. The ED 50 was also calculated.
| Antinociceptive model
The antianalgesic effect of naldemedine was determined with the tail-flick test-using a Tail-Flick Unit (model 7360; Ugo Basile, Italy)-and compared with methylnaltrexone, as previously described 17 with some modifications. Briefly, 6-week-old Crlj: WI male rats were allocated into seven groups (10-11 per group), based on the average latency of tail-flick at pretest and body weight, before the administration of naldemedine (1-30 mg kg −1 ) or vehicle, followed by subcutaneous morphine at 6 mg kg −1 or saline. To examine the influence of naldemedine on the analgesic effect of morphine, the rat tail-flick test was conducted as previously described. 22 Thermal stimulation was applied to the ventral surface of the tail, and the latency of the EC 50 , the concentration that produces half the maximal effect of the agonist; IC 50 , the concentration producing 50% inhibition.
; where IC 50 = the concentration of the antagonist producing 50% inhibition in the presence of agonist, and EC 50 = as described above. Mean of two independent experiments carried out in duplicate.
| Morphine withdrawal model
An osmotic pump (Model 2ML1, ALZET; Durect Corp., Cupertino, CA, USA) that injected subcutaneous morphine hydrochloride at a rate of 0.25 mg h −1 was implanted in the neck of anesthetized 6-week-old Jcl:
Wistar male rats (8 per group) to induce morphine dependence. After 5 days, naldemedine 0.01-7 mg kg −1 or vehicle was administered. Rats were observed for withdrawal signs immediately after dosing, and 1, 2, 4, 6, and 8 hours after dosing. Central withdrawal signs (jumping, wetdog shakes, and teeth chattering) and peripheral withdrawal signs (diarrhea and loss of body weight) were recorded. The number of times a rat jumped or had wet-dog shakes were counted for 20 minutes during each observation period. Diarrhea and teeth chattering were scored as follows: 0 = normal, 1 = slight to moderate, and 2 = marked. Loss of body weight was defined as the difference in body weight from before dosing to 8 hours after dosing (measured at the end of a 20-minutes observation period). Agonistic activity of naldemedine and methylnaltrexone for human μ-, δ-, and κ-opioid receptors; (C) Antagonistic activity of naldemedine and methylnaltrexone for human μ-, δ-, and κ-opioid receptors. Functional assays were performed using the was used to determine statistical significance, and the Dunn-Šidák method was used for multiplicity adjustments. When more than one noncensored data point was observed in postdose trials, the logrank test was conducted.
| Statistical analyses

| RE SULTS
| In vitro binding and enzyme inhibition activities of naldemedine and methylnaltrexone
Naldemedine showed potent binding affinities and antagonist activities for recombinant human μ-, δ-, and κ-opioid receptors (Table 1 and Figure 1 ), which were comparable between species (rats and humans; Table 1 ). By comparison, methylnaltrexone showed selective binding affinities and antagonist activities for the recombinant human μ-opioid receptor ( Table 1 for other receptors, ion channels, transporters, and enzymes tested were <50%. Results from the positive control substances, which were measured simultaneously, showed inhibition ratios ≥80%, confirming the validity of the measurement systems.
| In vivo effects of naldemedine and methylnaltrexone on small intestinal transit in rats
The in vivo effects of naldemedine were examined in a small intestinal transit model, where subcutaneous morphine (3 mg kg −1 ) or
The effect of naldemedine and methylnaltrexone on morphine-induced inhibition of small intestine transit in rats and the effect of naldemedine on oxycodone-induced inhibition of small intestine transit in rats. Each point represents the mean ± standard error for 10 rats in each group. *P < 0. oxycodone (1 mg kg −1 ) was administered in rat models to induce OIC.
The statistical analysis of the %MPE data showed that, compared with the vehicle control, subcutaneous morphine and oxycodone significantly inhibited small intestine transit (all P < 0.01). Naldemedine significantly repressed the opioid-induced inhibition of small intestinal transit in rats by subcutaneous morphine (P < 0.05 or P < 0.01 for naldemedine 0.03-10 mg kg −1 ), and oxycodone (P < 0.01 for naldemedine 0.03-3 mg kg −1 ; Figure 2 ). In the subcutaneous morphine-in- 
| Ex vivo effects of naldemedine on guinea pig large intestinal transit
To directly visualize the effect of naldemedine on large intestinal motility, we conducted a GIMM study using guinea pig distal colons.
Fecal pellets propelled smoothly from the oral to the anal side of the colons in the basal state without the presence of either test compound. Vehicle treatment with 3 μmol L −1 morphine was found to cause a significant decrease in the basal propulsive velocity (P < 0.01; Figure S2 ); therefore, 3 μmol L −1 morphine was selected as the morphine dose for the following experiments. Naldemedine (1 μmol L −1 )
alone had no effect on the basal propulsion rate ( Figure S3 ). when the same colon was exposed to vehicle with 3 μmol L −1 morphine, the propulsive motility was dramatically decreased, and the feces stopped at the oral side ( Figure 3B ; Video S1).
| Effect of naldemedine and methylnaltrexone on castor oil-induced diarrhea
Subcutaneous morphine-inhibited castor oil-induced diarrhea (P < 0.01) in rats, and pretreatment with naldemedine 0.03-1 mg kg −1 or methylnaltrexone 1-10 mg kg −1 significantly reversed this effect (Figure 4 ).
Naldemedine 0.1-1 mg kg −1 resulted in a diarrhea symptom score of 2 for all rats (intense liquefied diarrhea). The ED 50 values for naldemedine and methylnaltrexone were 0.01 and 0.585 mg kg −1 , respectively.
| Effect of naldemedine and methylnaltrexone on opioid analgesia
The influence of naldemedine on the analgesic effect of morphine was evaluated by measuring the latency of a rat to flick its tail following thermal stimulation. Subcutaneous morphine significantly prolonged the escape latency (P < 0.01 vs controls). Pretreatment (1 or 2 hours) with naldemedine (3-30 mg kg −1 ) did not alter the analgesic effects of morphine (Table 2) . Conversely, a significant but delayed inhibition of the analgesic effect of morphine was observed in rats treated with naldemedine at 10-30 mg kg −1 for longer intervals, as summarized in Table 2 . Naldemedine at a dose range of 3-7 mg kg −1
did not affect the analgesic effect of morphine at any of the time points tested. These results suggest that naldemedine (at 7 mg kg −1 )
and methylnaltrexone (at 10 mg kg −1 ; Table S1 ) do not affect the analgesic effect of morphine in a rat tail-flick test.
| Effect of naldemedine on opioid withdrawal
The influence of naldemedine on opioid withdrawal was evaluated by examining possible naldemedine-precipitated withdrawal symptoms in morphine-dependent rats. Treatment with naldemedine at oral doses of 0.01-3 mg kg −1 did not result in jumping behavior in morphine-dependent rats. However, naldemedine 1 mg kg −1 increased diarrhea scores (P < 0.05 at 2 hours postdose vs control); and naldemedine 3 mg kg −1 increased teeth chattering (P < 0.05 at 1, 4, and 8 hours postdose vs control) and diarrhea scores (P < 0.05 at 1 hour postdose vs control; Figure 5 ). Loss of body weight was noted at naldemedine doses ≥0.3 mg kg −1 (P < 0.05 for 0.3 mg kg
; P < 0.01 for 1 and 3 mg kg −1 vs control; Figure 5 ). In another study evaluating possible naldemedineprecipitated central withdrawal symptoms at higher doses of up to 7 mg kg −1 , naldemedine did not result in jumping behavior in morphinedependent rats, although a slight increase in the number of wet-dog shakes was observed at oral doses ≥5 mg kg −1 (P < 0.05 for the 5-and 7-mg kg −1 doses at 4 hours postdose; P < 0.01 for the 5-and 7-mg kg −1 doses at 6 hours postdose). The no-observed-effect levels of naldemedine for central and peripheral withdrawal signs are shown in Table 3 .
| D ISCUSS I ON
The key findings from this study are that naldemedine elicits anticonstipation-like effects induced by an opioid in three constipation
Effect of naldemedine and methylnaltrexone on morphine-induced inhibition of castor oil-induced diarrhea in rats. Each bar represents the mean ± standard error for 11 rats in each group. *P < 0.05, **P < 0.01 versus vehicle + morphine. receptors. 23 However, both naloxegol 23 and methylnaltrexone (Table 1) but not by δ-and κ-opioid antagonists. 25 On the other hand, all three opioid receptors are localized to the enteric nervous system. 26 In addition, μ/δ but not μ/κ co-expression has been observed in rat interstitial cells located adjacent to myenteric plexus structures. Castor oil is known to release ricinoleic acid followed by alterations in jejunal, ileal, and colonic ion transport and water flux [29] [30] [31] The values are the median of normalized latency for tail withdrawal response in each group. In parentheses, quartiles of 25% and 75% are shown. n indicates the number of rats/group/time point. † † P < 0.01 compared to the vehicle-saline group (log-rank test).
* P < 0.05, **P < 0.01 compared with the vehicle-morphine group (log-rank test followed by Dunn-Sidak method for multiplicity adjustments).
Experiments were also conducted to directly visualize the effect of naldemedine on morphine-induced delayed propulsion of a fecal pellet in the large intestine. This method has previously been used to examine the restorative effect of naloxone on DAMGO-suppressed propulsive motility. 18 Our results showed that naldemedine improved delayed large intestinal transit caused by morphine in a dose-dependent manner. As morphine is suggested to act on small and large intestinal muscle contraction, thereby reducing peristaltic movement and consequently inducing constipation, 33 naldemedine may have restored propulsion by antagonizing such contraction.
In the preclinical setting, it has been reported that OIC in the small intestine may be regulated by central and peripheral opioid receptors, whereas OIC in the large intestine may be regulated by the peripheral action of opioid receptors. 25, 34 Therefore, our methods for the small and large intestinal measurement were suitable to investigate the characteristics of each intestinal region. Furthermore, the small intestine (but not the large intestine) gains tolerance to opioids through chronic exposure. This difference is reflected in the observation that both small and large intestines contribute to the early stages of OIC, whereas chronic OIC is driven mainly by the large intestine. 25, 34 Because naldemedine improved both small and large intestinal transits, and showed efficacy in patients with chronic OIC, 35 we consider naldemedine as a potential antagonist that improves both acute and chronic stages of OIC.
The antinociceptive model confirmed that the analgesic effect of opioids was maintained even after administration of high naloxone-a μ-opioid receptor antagonist with the capability to cross the BBB-the naldemedine dose range for this delayed antianalgesic effect is notably higher than that for anticonstipation. 36 Correspondingly, for naldemedine, the highest dose of drug without an observed antianalgesic effect was 233-fold higher than the ED 50 of naldemedine in the small intestinal transit study. By comparison, for methylnaltrexone-another PAMORA used to treat OIC-the highest dose of drug without an observed antianalgesic effect was only 2.24-fold higher than the ED 50 of methylnaltrexone in the small intestinal transit study. These results suggest lower BBB penetration by naldemedine compared with methylnaltrexone.
In a study describing the discovery of naldemedine, naldemedine showed high oral bioavailability but poor distribution throughout the CNS. Moreover, the maximum plasma concentration of naldemedine is enough to antagonize the peripheral μ-opioid receptor based on a K b value of 0.5 nmol L −1 (antagonist activity). There was no enterohepatic recycling in bile duct-cannulated tandem rats using
[carbonyl 14 C]-naldemedine, although hepatic portal vein/bile duct levels were not measured (data not shown). These data support a hypothesis that the predominant effects of naldemedine to enteric nerve are associated with systemic circulation, rather than the CNS and direct effect from intestinal lumen.
Central opioid withdrawal symptoms were not observed with up to 1 mg kg −1 of naldemedine. This result demonstrates that the no-observed-effect levels of naldemedine, which underlie its antianalgesic effects (3 mg kg −1 ), and centrally mediated withdrawal symptoms (1 mg kg −1 ), are at least 100 times and 30 times, respectively, as high as the naldemedine ED 50 for anticonstipation effects (0.03 mg kg −1 ) under current experimental conditions. These wide margins reinforce naldemedine as a peripherally acting compound.
In conclusion, data from in vitro and in vivo studies indicate that naldemedine has a potent binding affinity and antagonistic activity to the μ-, δ-, and κ-opioid receptors that is different from that of methylnaltrexone. The concentration of naldemedine necessary to inhibit the constipating effect of opioids is much lower than the concentration of naldemedine that interferes with opioid analgesia. The large difference between these concentrations seems to be even wider than the difference in concentrations seen with methylnaltrexone. These data support the clinical results of naldemedine as a treatment for patients with OIC, with minimal concern for interference of the action of opioids in the CNS. 37 
